Similarly, in AML cells, glutaminolysis may represent a therapeutic vulnerability when paired with specific tyrosine kinase inhibitors in FLT3-ITD-driven leukaemia [134]. This evidence concerns the gene FLT3 and acute myeloid leukemia.